PTIE - Pain Therapeutics, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD

Pain Therapeutics, Inc.

7801 North Capital of Texas Highway
Suite 260
Austin, TX 78731
United States

Full Time Employees9

Key Executives

Mr. Remi BarbierFounder, Chairman, Chief Exec. Officer, Pres and Corp. Sec.1.16MN/A58
Dr. Nadav Friedmann Ph.D., M.D.Chief Operating Officer, Chief Medical Officer and Director462.5kN/A75
Mr. Michael J. O'Donnell Esq.Sec. and DirectorN/AN/A60
Dr. Michael Marsman Pharm.D.Sr. VP of Regulatory AffairsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Pain Therapeutics, Inc., a biopharmaceutical company, develops drugs for treating nervous system in the United States. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone for pain relief. It also develops FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; and PTI-125, a small molecule drug candidate to treat Alzheimer's disease and other neurological disorders. The company was founded in 1998 and is based in Austin, Texas.

Corporate Governance

Pain Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.